CLS
Wall Street’s latest flex
JPMorgan Chase & Co. just bumped Celestica’s price target to $410 from $360 and stuck with an Overweight rating. That’s basically analyst-speak for: “We still like the story, and we think there’s room to run.”
The weird part? The stock is already flying
Celestica wasn’t exactly begging for attention. The shares recently traded around $384.19, which means the new target only implies about 6.7% upside from here. Not exactly moonshot territory — more like “still room left in the elevator.”
And JPMorgan isn’t alone in sounding upbeat. The broader analyst crowd has been lifting targets too, with the average price target sitting around $361.78 and the consensus leaning buy. When analysts start nudging their numbers higher in a crowded parade, you usually pay attention.
But insiders are still unloading
Here’s the part that makes the story a little less champagne-y: insiders have sold about 297,923 shares worth roughly $88 million over the past three months. That doesn’t automatically mean trouble — executives sell for all kinds of reasons — but it does give you a useful reality check when the stock is already running hot.
Big picture
For investors, this is another vote of confidence in Celestica’s rally, but not a brand-new thesis. The stock already looks pricey relative to where it’s been, so the question isn’t whether Wall Street likes it. It’s whether Celestica can keep giving analysts a reason to raise the bar again.